Prostaglandin F2alpha: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{Drugbox | |||
| Verifiedfields = changed | |||
| Watchedfields = changed | |||
| verifiedrevid = 406310380 | |||
| IUPAC_name = (''Z'')-7-[(1''R'',2''R'',3''R'',5''S'')-3,5-dihydroxy-2-[(''E'',3''S'')- 3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid | |||
| image = Dinoprost.png | |||
| drug_name = Dinoprost Tromethamine | |||
<!--Clinical data--> | |||
| tradename = | |||
| Drugs.com = {{drugs.com|international|dinoprost-tromethamine}} | |||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | |||
| pregnancy_US = <!-- A / B / C / D / X --> | |||
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 --> | |||
| legal_UK = <!-- GSL / P / POM / CD --> | |||
| legal_US = <!-- OTC / Rx-only --> | |||
| routes_of_administration = [[Intravenous therapy|Intravenous]] (to induce labor), [[amniotic fluid|intra-amniotic]] (to induce abortion) | |||
<!--Pharmacokinetic data--> | |||
| elimination_half-life = 3 to 6 hours in [[amniotic fluid]], less than 1 minute in [[blood plasma]] | |||
<!--Identifiers--> | |||
| CASNo_Ref = {{cascite}} | |||
| CAS_number_Ref = {{cascite|correct|??}} | |||
| CAS_number = 551-11-1 | |||
| CAS_supplemental = {{CAS|38562-01-5}} | |||
| ATC_prefix = G02 | |||
| ATC_suffix = AD01 | |||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | |||
| ChemSpiderID = 4444062 | |||
| smiles = O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCCCC | |||
| InChI = 1/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,18-,19+/m0/s1 | |||
| InChIKey = PXGPLTODNUVGFL-YNNPMVKQBA | |||
| StdInChI_Ref = {{stdinchicite|changed|chemspider}} | |||
| StdInChI = 1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,18-,19+/m0/s1 | |||
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} | |||
| StdInChIKey = PXGPLTODNUVGFL-YNNPMVKQSA-N | |||
| PubChem = 5280363 | |||
| IUPHAR_ligand = 1884 | |||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | |||
| DrugBank = DB01160 | |||
| KEGG_Ref = {{keggcite|changed|kegg}} | |||
| KEGG = D01352 | |||
| ChEMBL_Ref = {{ebicite|changed|EBI}} | |||
| ChEMBL = 815 | |||
<!--Chemical data--> | |||
| C=20 | H=34 | O=5 | |||
| molecular_weight = 354.48 g/mol | |||
}} | |||
__NOTOC__ | |||
{{SI}} | {{SI}} | ||
{{ | {{CMG}} | ||
==Overview== | |||
'''[[Prostaglandin]] F<sub>2α</sub>''' ('''PGF<sub>2α</sub>''' in [[prostanoid]] nomenclature), pharmaceutically termed '''dinoprost''' ([[International Nonproprietary Name|INN]]), is a naturally occurring prostaglandin used in medicine to [[induction (birth)|induce labor]] and as an [[abortifacient]]. | |||
In domestic mammals, it is produced by the uterus when stimulated by [[oxytocin]], in the event that there has been no implantation during the follicular phase. It acts on the [[corpus luteum]] to cause [[luteolysis]], forming a [[corpus albicans]] and stopping the production of progesterone. Action of PGF<sub>2α</sub> is dependent on the number of receptors on the corpus luteum membrane. | |||
The PGF<sub>2α</sub> isoform ''8-iso-PGF<sub>2α</sub>'' was found in significantly increased amounts in patients with [[endometriosis]], thus being a potential causative link in endometriosis-associated oxidative stress.<ref>{{cite doi|10.1016/j.fertnstert.2009.01.141}}</ref> | |||
==Mechanism of action== | |||
{{further2|[[Prostaglandin F2α receptor]]}} | |||
PGF<sub>2α</sub> acts by binding to the [[prostaglandin F2α receptor]]. | |||
==Synthesis== | |||
In 2012 a concise and highly stereoselective total synthesis of PGF<sub>2α</sub> was described.<ref name="coulthard2012">{{cite doi|10.1038/nature11411}}</ref> The synthesis requires only seven steps, a huge improvement on the original 17-steps synthesis of Corey and Cheng,<ref name="coreybook">{{cite book|title=The Logic of Chemical Synthesis|first1=E.J.|last1=Corey|first2=X.M.|last2=Cheng|publisher=Wiley|year=1995}}</ref> and uses 2,5-dimethoxytetrahydrofuran as a starting reagent, with ''S''-[[proline]] as an asymmetric catalyst. | |||
==Analogs== | |||
The following medications are [[Prostaglandin analogue|analogs]] of prostaglandin F<sub>2α</sub>: | |||
*[[Latanoprost]] | |||
*[[Bimatoprost]] | |||
*[[Travoprost]] | |||
*[[Carboprost]] | |||
== | == References == | ||
{{Reflist|2}} | |||
{{ | {{Prostaglandins}} | ||
{{Oxytocics}} | |||
[[Category:Abortifacients]] | |||
[[Category:Prostaglandins|F2]] | |||
Revision as of 12:51, 21 April 2015
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Intravenous (to induce labor), intra-amniotic (to induce abortion) |
| ATC code | |
| Pharmacokinetic data | |
| Elimination half-life | 3 to 6 hours in amniotic fluid, less than 1 minute in blood plasma |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
| ChEMBL | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C20H34O5 |
| Molar mass | 354.48 g/mol |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Prostaglandin F2α (PGF2α in prostanoid nomenclature), pharmaceutically termed dinoprost (INN), is a naturally occurring prostaglandin used in medicine to induce labor and as an abortifacient.
In domestic mammals, it is produced by the uterus when stimulated by oxytocin, in the event that there has been no implantation during the follicular phase. It acts on the corpus luteum to cause luteolysis, forming a corpus albicans and stopping the production of progesterone. Action of PGF2α is dependent on the number of receptors on the corpus luteum membrane.
The PGF2α isoform 8-iso-PGF2α was found in significantly increased amounts in patients with endometriosis, thus being a potential causative link in endometriosis-associated oxidative stress.[1]
Mechanism of action
Template:Further2 PGF2α acts by binding to the prostaglandin F2α receptor.
Synthesis
In 2012 a concise and highly stereoselective total synthesis of PGF2α was described.[2] The synthesis requires only seven steps, a huge improvement on the original 17-steps synthesis of Corey and Cheng,[3] and uses 2,5-dimethoxytetrahydrofuran as a starting reagent, with S-proline as an asymmetric catalyst.
Analogs
The following medications are analogs of prostaglandin F2α:
References
- ↑ Template:Cite doi
- ↑ Template:Cite doi
- ↑ Corey, E.J.; Cheng, X.M. (1995). The Logic of Chemical Synthesis. Wiley.
Categories:
- Pages with script errors
- Template:drugs.com link with non-standard subpage
- Articles with changed ChemSpider identifier
- Articles with changed KEGG identifier
- Articles with changed EBI identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles with changed InChI identifier
- Chemical articles with unknown parameter in Infobox drug
- Infobox drug articles with non-default infobox title
- Articles without UNII source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Abortifacients
- Prostaglandins